Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
CancerNetwork® spoke with Taliya Lantsman, MD, a hematology and oncology fellow at Beth Israel Deaconess Medical Center, about considerations for sequencing dostarlimab-gxly (Jemperli) and chemotherapy with other therapeutic options in patients with advanced endometrial cancer, as well as key differences between the real-world analysis she conducted and those of thephase 3 RUBY trial (NCT03981796).1,2Lantsman presented a real-world, retrospective analysis on the efficacy and safety of dostarlimab combination therapy in advanced endometrial cancer at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO).
Lantsman began by iterating the survival benefit of dostarlimab with platinum-based chemotherapy, a combination that has demonstrated enhanced progression-free survival (PFS) and overall survival (OS) in patients with advanced endometrial cancer. She further expressed that she recommends dostarlimab with chemotherapy based on phase 3 RUBY trial findings.
Then, despite emphasizing some differences between the real-world cohort in the analysis she presented at SGO and the phase 3 RUBY trial population, she explained that one key difference was a disparity in the inclusion of patients with comorbidities on respective studies. Furthermore, her trial included patients with an ECOG performance status of 2, which the phase 3 RUBY trial did not assess.
Finally, Lantsman expressed that the most prominent difference between the analysis she conducted and the RUBY trial was regarding the receipt of radiation for stage III disease, which was done in her analysis but not in the RUBY trial.
Transcript:
At this point, following what RUBY demonstrates––that adding dostarlimab to upfront platinum-based chemotherapy demonstrates a PFS and OS benefit for patients [with advanced endometrial cancer]—I would continue to recommend, based on those [RUBY] findings, to use that treatment.
We found a lot of similarities [between the real-world population and patients enrolled on the RUBY trial]. Some differences [include the fact] that we were looking at patients who had other comorbidities who may not have been included in this trial. We also included patients who had an ECOG [performance status score of] 2, which was not evaluated in the trial. The biggest difference that we saw between our patients and the trial was what we [were] doing about radiation. Our patients did, in fact, receive radiation if they [had] stage III disease.
References
- Powell MA, Auranen A, Willmott LJ, et al. Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial. Presented at: Society of Gynecologic Oncology 2024 Annual Meeting on Women’s Cancer; March 16-18, 2024; San Diego, CA.
- Lantsman T, Jia L, Edmiston C, Shea M, Widick P. Real-world RUBY: safety and efficacy of combination chemotherapy plus dostarlimab in advanced endometrial cancer. Presented at: 2025 SGO Annual Meeting on Women’s Cancer; March 14-17, 2025; Seattle, WA. Abstract 1280.
